Compare LADR & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LADR | SPTX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2013 | 2026 |
| Metric | LADR | SPTX |
|---|---|---|
| Price | $9.92 | $24.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.25 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 104.0K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 8.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.66 | N/A |
| Revenue Next Year | $16.92 | N/A |
| P/E Ratio | $71.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.38 | $17.59 |
| 52 Week High | $11.92 | $26.32 |
| Indicator | LADR | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 65.81 |
| Support Level | $9.56 | $18.72 |
| Resistance Level | $10.45 | N/A |
| Average True Range (ATR) | 0.23 | 1.44 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 47.52 | 70.22 |
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.